ANA Investigates

The latest in neurology and neuroscience, each month from the ANA.

ANA members are offered the opportunity to claim AMA PRA Category 1 Credits™. Please follow this link to access CME information and instructions.

Listen to ANA Investigates here or on your podcast application of choice. To receive automatic updates when new episodes are released, subscribe on Apple | Google | Spotify

Submit Ideas for Future Episodes

Access CME

View Episode Archive

Latest episode

ANA Investigates Disruptive Technologies: Neuroethics Role in Advancing Innovation

Neurotechnology like DBS or transcranial magnetic stimulation have clear benefits in diagnosis and therapy ... what about recent accelerated development from tech entrepreneurs to harness cognitive pathways for everyday tasks?
Episode Description

Neurotechnology like DBS or transcranial magnetic stimulation have clear benefits in diagnosis and therapy and are largely embraced by the medical community. But what about recent accelerated development from tech entrepreneurs to harness cognitive pathways for everyday tasks? This is referred to as brain computer interface technology or BCI. Commercial products such as Neuralink, attempt to implant chips promising to link brain activity with tasks such as accessing phones or cars. This brings up real questions on autonomy, privacy, and medical implications, but is there more to these technological advancements that could provide medical benefit for our patients? We discuss the commercial and medical aspects surrounding BCI technology and the physician and scientist’s role in this rapidly evolving field with Dr. Karen Rommelfanger, the founder and director of the Neuroethics Program at Emory University and now the founder of the world’s first think and DO tank dedicated wholly to neuroethics called the Institute of Neuroethics. She also serves as a member of the BRAIN Initiative’s Neuroethics Working Group and was on the advisory council to the director of the National Institutes of Health (NIH) for BRAIN 2025. Series 4, Episode 1.

Featuring
  • Interviewer/Producer: Dr. Rohini Samudralwar, University of Pennsylvania
  • Guest: Dr. Karen Rommelfanger, Emory University & Institute of Neuroethics
Disclosures

None

Read Full Episode Description

ANA Investigates Genetics in Epilepsies

Now, making a genetic diagnosis in epilepsy isn’t just important for family planning and prognostication - these diagnoses can also improve patients’ care starting at the moment of diagnosis.
Episode Description

The role of genetics in both pediatric and adult epilepsies is expanding. Now, making a genetic diagnosis in epilepsy isn’t just important for family planning and prognostication - these diagnoses can also improve patients’ care starting at the moment of diagnosis. Our guest today, Ingrid Scheffer, is a leader in gene discovery in epilepsy. Dr. Scheffer is a Laureate Professor of Pediatric Neurology at the University of Melbourne, and she directs the Children's Epilepsy Research Center at Austin Health. She says while there’s still a long way to go before precision medicine is available for the hundreds of known genetic epilepsies, her patients are already benefiting from genetic testing, in many ways. Dr. Scheffer was interviewed by ANA Investigates Producer and epileptologist Dr. Rohit Das of UT Southwestern Medical Center. Series 3, Episode 12.

Featuring
  • Guest: Ingrid Scheffer, AO FRS FAA FAHMS, University of Melbourne
  • Interviewer/Producer: Rohit Das, MD, UT Southwestern
Disclosures

In the past 24 months, Ingrid Scheffer has consulted for Atheneum Partners, Biohaven Pharmaceuticals Inc, Care Beyond Diagnosis, Epilepsy Consortium and Zynerba Pharmaceuticals, has served as an investigator for Anavex Life Sciences, Cerebral Therapeutics, Cerecin Inc, Cereval Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceutical, Zogenix and Zynerba; received speaker honoraria from Biocodex, BioMarin, Chiesi, Liva Nova and UCB; received funding for travel from Biomarin, Eisai and UCB; and served on scientific advisory boards for Bellberry Ltd, BioMarin, Chiesi, Eisai, Encoded Therapeutics, Knopp Biosciences, Rogcon, Takeda Pharmaceuticals and UCB. Ingrid Scheffer may accrue future revenue on pending patent WO2009/086591: Diagnostic And Therapeutic Methods For EFMR (Epilepsy And Mental Retardation Limited To Females); has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies (WO/2006/133508); she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) [PRRT2] WO/2013/059884 with royalties paid.

Read Full Episode Description

ANA Investigates Teleneurology and Healthcare Equity

Series 3, Episode 11
Equitable tele-neurologic care starts with first identifying disparities, then identifying how to overcome them – learn about both with Dr. Lee Schwamm on the latest ANA Investigates. Series 3, Episode 11.
Episode Description

Equitable tele-neurologic care starts with first identifying disparities, then identifying how to overcome them – learn about both with Dr. Lee Schwamm on the latest ANA Investigates. Series 3, Episode 11.

Featuring
  • Guest: Dr. Lee Schwamm, C Miller Fisher Endowed Chair in Vascular Neurology and the Director of the Center for TeleHealth at Massachusetts General Hospital, Professor of Neurology at Harvard Medical School and Vice President for Digital Patient Experience at the Mass General Bri
  • Interviewer/Producer: Dr. Amanda Jagolino-Cole, Director of the UT Teleneurology Division at McGovern Medical School at the University of Texas Health Science Center in Houston
Disclosures
  • Disclosures: None
Read Full Episode Description

*Special Episode* ANA Investigates Potential Fabrication in AD Research Images

Late last month, the journal Science published an investigative report that accused a much-cited publication in Alzheimer’s disease... of fabricating scientific images.
Episode Description

Late last month, the journal Science published an investigative report that accused a much-cited publication in Alzheimer’s disease... of fabricating scientific images. The study under scrutiny was published in Nature in 2006 by Sylvain Lesné and colleagues. It claimed that an amyloid oligomer called Aβ*56 impaired memory in mice. The recent Science report found potential fabrication in the images used in that paper... and concluded that this potential fabrication threatens the amyloid hypothesis in Alzheimer’s disease. Here at ANA Investigates, we decided we needed to ask the experts about that. Their conversation will help us understand the impact of the recent investigative report on the field of Alzheimer’s research. Series 3, Episode 10.

Featuring
  • Guest: Dr. Richard O’Brien, Alzheimer’s researcher, Chair of the Department of Neurology at Duke University
  • Interviewer/Producer: Dr. Erik Roberson, Alzheimer’s researcher, endowed Professor of Neurology, and Director of the Alzheimer’s Disease Center at the University of Alabama at Birmingham
Disclosures

none

 

Read Full Episode Description

ANA Investigates Updates in Autoimmune Encephalitis, part 2, therapeutics

Last month on the podcast, we talked about updates in the diagnosis of autoimmune encephalitis. This month we turn to advances in the treatment of autoimmune encephalitis.
Episode Description

Last month on the podcast, we talked about updates in the diagnosis of autoimmune encephalitis. This month we turn to advances in the treatment of autoimmune encephalitis. Treating these conditions has traditionally been practitioner-dependent, and currently no FDA-approved therapies exist. But that’s beginning to change. Series 3, Episode 9.

Featuring
  • Guest: Dr. Maarten Titulaer, Erasmus MC University Medical Center
  • Interviewer/Producer: Dr. Rohini Samudralwar, University of Pennsylvania
Disclosures

Dr. Titulaer disclosed that his institution receives consulting funds form UCB, Viela Bio (Horizon), and CSL Behring, he is the co-investigator on the ExTinguish trial funded in part by Horizon, and a PI IVIG trial funded by CSL Behring.

Read Full Episode Description

ANA Investigates Updates in Autoimmune Encephalitis, part 1, diagnostics

On today's episode, Dr. Adeline Goss interviews Dr. Andrew McKeon on updates on diagnostics for part one of a two-part series on autoimmune encephalitis.
Episode Description

On today's episode, Dr. Adeline Goss interviews Dr. Andrew McKeon on updates on diagnostics for part one of a two-part series on autoimmune encephalitis. Series 3, Episode 8.

Featuring
  • Guest: Andrew McKeon,, M.B., B.Ch., M.D., Mayo Clinic College of Medicine and Science
  • Interviewer/Producer: Adeline Goss, MD, Highland Hospital
Disclosures

Dr. McKeon disclosed that he is a consultant for Johnson & Roche Genentech; and receives royalties from Euroimmun

Read Full Episode Description

ANA Investigates TIA

On today's episode, we discuss the term "TIA" and the current debate as it pertains to advances in stroke diagnostics that have led some to propose that we retire the term. Series 3, Episode 7.
Episode Description

On today's episode, we discuss the term "TIA" and the current debate as it pertains to advances in stroke diagnostics that have led some to propose that we retire the term. Series 3, Episode 7.

 

Featuring
  • Guest: Clay, Johnston, MD, PhD, The University of Texas at Austin
  • Interviewer/Producer: Megan Richie, MD, UCSF
Disclosures

Dr. Johnston disclosed research  support from AstraZeneca for the THALES trial.

Read Full Episode Description

ANA Investigates Neurobiology of Burnout

Burnt out by talking about burnout? Please join us for a podcast with Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University.
Episode Description

Burnt out by talking about burnout? Please join us for a podcast with Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University, to investigate what goes on in the brain that leads to burnout and how this can direct our efforts to reduce burnout. Series 3, Episode 6.

Featuring
  • Guest: Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University
  • Interviewer/Producer: Dr. Amanda Jagolino-Cole, McGovern Medical at the University of Texas Health Science Center in Houston
Read Full Episode Description

ANA Investigates Biomarkers for Alzheimer's Disease

On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease.
Episode Description

On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease. We know that amyloid beta and tau protein deposit long before patients with Alzheimer’s develop symptoms. If we could use biomarkers to detect this pathology early, and treat patients early, could we prevent the progression to dementia? Our guests today are leaders in the development of biomarkers for Alzheimer’s disease - Dr. Suzanne Schindler, Associate Professor of Neurology at Washington University in St. Louis and Dr. Gil Rabinovici, Professor of Neurology and Radiology at the University of California San Francisco. They’ll talk with Dr. Doug Ney of UC Denver about the expanding role of biomarkers in Alzheimer’s prevention and treatment. Series 3, Episode 5.

Featuring
  • Guest: Dr. Suzanne Schindler, Associate Professor of Neurology at Washington University in St. Louis
  • Guest: Dr. Gil Rabinovici, Professor of Neurology and Radiology at the University of California San Francisco
  • Interviewer/Producer: Dr. Doug Ney, UC Denver
Disclosures

Disclosures: Dr. Schindler disclosed that C2N Diagnostics provided data free of cost for her team to analyze. Dr. Rabinovici disclosed that he leads the New IDEAS study and has received research funding from Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging, Genentech; and is on scientific advisory boards for Eisai, J&J, Genentech, Eli Lilly, and Roche.

Read Full Episode Description

ANA Investigates Curing Coma

Can coma be “cured”? On this podcast, we talk to Dr. Claude Hemphill and Dr. Romer Geocadin of the Curing Coma Campaign.
Episode Description

Can coma be “cured”? On this podcast, we talk to Dr. Claude Hemphill and Dr. Romer Geocadin of the Curing Coma Campaign. Series 3, Episode 4 https://www.curingcoma.org/events2/world-coma-day

Below are articles the guests of this podcast wished to share with the listeners:

 

 

<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/22155224/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/000000/" height="90" width="100%" scrolling="no"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>

Featuring
  • Guest: Romer Geocadin, MD, Johns Hopkins University
  • Guest: Claude Hemphill, MD, University of California San Francisco
  • Interviewer/Producer: Dr. Adeline Goss, Highland Hospital
Disclosures

none

Read Full Episode Description

ANA Investigates Basilar Artery Stroke

Treatment of stroke has changed dramatically in the past decade, with the advent of perfusion imaging and an expanded time window for mechanical thrombectomy. Thrombectomy is now standard of care for eligible patients.
Episode Description

Treatment of stroke has changed dramatically in the past decade, with the advent of perfusion imaging and an expanded time window for mechanical thrombectomy. Thrombectomy is now standard of care for eligible patients. But while data clearly supports the use of thrombectomy for certain patients with anterior circulation strokes, the benefit of thrombectomy for patients with basilar artery occlusions remains unproven. Today we’ll talk to a vascular neurologist and a neurointerventional surgeon who are trying to better define which patients with basilar artery occlusion may benefit from thrombectomy -- and which patients may not. Series 3, Episode 3. 

Featuring
  • Guest: Dr. Carlo Cereda, vascular neurologist, head of the EOC Comprehensive Stroke Center at the Neurocenter of Southern Switzerland and Faculty of Biomedical Sciences, Università della Svizzera Italiana in Lugano
  • Guest: Dr. Jeremy Heit, Assistant Professor of Radiology and of Neurosurgery and the interim Chief of Neuroradiology at Stanford University
  • Interviewer/Producer: Dr. Michelle Johansen, Assistant Professor of Neurology, Johns Hopkins Medicine
Disclosures

Disclosures: Dr. Heit disclosed that he consults for Medtronic and MicroVention, and consults and is a member of medical and scientific advisory board for iSchemaView, Inc., and Dr. Cereda disclosed that he is a advisory board for iSchemaView, Inc.

Read Full Episode Description

ANA Investigates FND

On today’s show we’ll focus on functional neurological disorder, or FND -- a wide range of conditions including non-epileptic seizures and functional weakness, dystonia and tremor.
Episode Description

On today’s show we’ll focus on functional neurological disorder, or FND -- a wide range of conditions including non-epileptic seizures and functional weakness, dystonia and tremor. These conditions are common and can cause serious disability. But what are these conditions, exactly? What have functional neuroimaging and other tools taught us about their pathophysiology, diagnosis, and treatment? Series 3, Episode 2.

Featuring
  • Guest: Dr. Sara Finkelstein, neurologist and specialist in functional neurological disorder at Massachusetts General Hospital
  • Interviewer/Producer: Dr. Adeline Goss, Highland Hospital
Disclosures

none

Read Full Episode Description

ANA Investigates Neurostimulation

Some patients with medically refractory epilepsy are offered surgeries to implant devices that electrically stimulate the nervous system and actually modulate neural networks over time.
Episode Description

Some patients with medically refractory epilepsy are offered surgeries to implant devices that electrically stimulate the nervous system and actually modulate neural networks over time. On this episode of ANA Investigates, Dr. Vikram Rao of the UCSF Weill Institute for Neurosciences discusses how these neurostimulation devices can reduce seizure burden, along with a range of other potential benefits.‌ Series 3, Episode 1.

Featuring
  • Guest: Dr. Vikram Rao, epileptologist and Associate Professor of Neurology at the UCSF Weill Institute for Neurosciences
  • Interviewer/Producer: Dr. Rohit Das, epileptologist at UT Southwestern Medical Center‌‌
Disclosures

Dr. Rao disclosed the following relevant relationships for CME purposes: NeuroPace-Consultant; LivaNova-Scientific Advisory Board

Read Full Episode Description